Crystalline SSTR2 Modulator Salts for Selective Somatostatin Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing somatostatin modulators lack specificity in targeting somatostatin receptor subtype 2 (SSTR2) for effective treatment of conditions like acromegaly, neuroendocrine tumors, and other disorders, leading to potential side effects and inefficiencies.
Innovation Solution
Development of crystalline and amorphous forms of 3-(4-(4-aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl)-2-hydroxybenzonitrile dimesylate, characterized by specific X-ray powder diffraction patterns and thermal properties, to selectively modulate SSTR2 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for acromegaly and neuroendocrine tumors are used, then therapeutic effects are achieved, but unwanted side effects occur due to lack of selective targeting of somatostatin receptor subtypes
Solution Approach 1:
The patent applies local quality by designing the somatostatin modulator compound with specific molecular characteristics that enable selective binding to SSTR2 subtype receptors. The compound's structural features (including the dimesylate salt form and specific quinolin-6-yl substitution pattern) create localized interaction properties that preferentially engage SSTR2 over other somatostatin receptor subtypes, thereby achieving selective targeting and reducing off-target side effects
2Ease of manufacture
If amorphous solid form of the compound is used, then manufacturing flexibility is improved, but stability and storage characteristics deteriorate
Solution Approach 1:
The patent applies parameter changes by systematically investigating and characterizing multiple solid forms (amorphous, crystalline Pattern A, crystalline hydrate Pattern B) of the compound. Each solid form exhibits different physical parameters including XRPD patterns, DSC thermograms, TGA profiles, and solubility characteristics. This enables selection of the appropriate solid form based on specific manufacturing and storage requirements, balancing ease of manufacture with stability
3Stability of the object's composition
If crystalline form of the compound is used, then storage stability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-characterizing the crystalline forms (Pattern A and hydrate Pattern B) with detailed XRPD patterns, DSC thermograms, and TGA profiles before manufacturing. This advance characterization establishes clear identification criteria and quality standards, enabling manufacturers to selectively produce the desired crystalline form using optimized protocols, thereby reducing manufacturing complexity while ensuring storage stability
Data Source
AI summary
Described herein are pharmaceutically acceptable salts of a somatostatin modulator, crystalline forms of the pharmaceutically acceptable salts of the somatostatin modulator, methods of making such salts and crystalline forms, pharmaceutical compositions and medicaments comprising such salts and crystalline forms, and methods of using such salts and crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.